BIO-TECHNE Corp Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31)
BIO-TECHNE Corp (TECH) reported Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) of -$3.90 million for the 3-month period ending 2015-09-30, per its 10-Q filed 2015-11-09.
Discontinued › Income Statement › Other Income
us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 · last filed 2015-11-09
- BIO-TECHNE Corp available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for the quarter ending 2015-09-30 was -$3.90M.
| Period end | Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) 3 month |
|---|---|
| 2015-09-30 | -$3.90M 10-Q · filed 2015-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |